Developing Disruptive Biofarming Technology for the Cannabis Industry
Canna-V-Cell Sciences Inc. (CSE:CNVC) is the exclusive international cannabis licensee for the patent-protected BioHarvest technology, a large-scale plant cell growth technology capable of producing active plant ingredients without having to grow the plant itself. Canna-V-Cell is adapting this technology to create the active ingredients found in cannabis so that the company can become a leading medical and recreational cannabis supplier.
The global cannabis market is expected to reach US$66.3 billion by the end of 2025, according to a report by Grand View Research. Most of the growth is being driven by the adoption of cannabis in the pharmaceutical industry as new products are being developed to treat severe medical conditions, such as cancer, Parkinsons, Alzheimers and arthritis. However, issues with cannabis supply can affect the long-term growth of the industry as more countries initiate cannabis programs and legislative reforms, making it difficult for licensed producers to provide enough high-quality products to meet the demand.
Canna-V-Cell believes it has developed a solution to the cannabis supply and consistency problem with the BioHarvest technology called biofarming. The technology isolates the active ingredient cells from the cannabis plant before multiplying (growing) them in the biofarming process. The technology can do this without using any solvent extraction, genetic modification or synthetic molecular processing techniques. To facilitate its biofarming operation, Canna-V-Cell has built a production facility that can produce approximately one ton of cannabis active ingredients powder (equivalent to the cannabis plant dried bud) per year in a 100-square-meter space. The company intends to increase its production to 10 tons per year by 2022.
The company is currently in the feasibility testing phase of development but expects to release its products by 2020. As of September 2019, the company produced its first cannabis cells in suspension with a cannabinoid profile that was identical to the original cannabis plant without growing the plant. Using a B2B business model, Canna-V-Cell intends to sell its active ingredients as a powder for repackaging and formulation to its clients. In addition, the company may license the technology in order to accelerate the industry adoption curve.
BioHarvest has already demonstrated the feasibility and viability of the biofarming technology through its commercially available product called VINIA. This product is based on red grapes. It contains all the healthy ingredients (polyphenols) without the sugar, calories or alcohol found in wine and grapes. Consumers can currently purchase the powder in a 400-milligram daily dose.
Canna-V-Cell Company Highlights
- Over 10 years and $30 million have been invested in developing the biofarming technology.
- The biofarming technology is expected to ease bottlenecks in the cannabis industry.
- Canna-V-Cell will be utilizing a B2B business model and will supply its active ingredient products as a powder for repackaging by its clients.
- The company is expecting to launch its products by 2020.
- The current production capacity of the company’s facility is 2 tons per year and is expected to increase to 10 tons per year.
- Canna-V-Cell’s seasoned management team has a track record of success behind them.
- Bioharvest (the inventor and licensor of biofarming) notably holds 50 percent of shares.
*Disclaimer: INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Canna-V-Cell Sciences Inc. and seek advice from a qualified investment advisor.